Could Buying Freeport-McMoRan (FCX) Stock Today Set You Up for Life? Demand for copper is growing rapidly, as it's used in data centers, wind turbines, and electric vehicles.
Prediction: This Brilliant ETF Will Crush the S&P 500 Over the Next 20 Years Value stocks and small-caps could be ready for the spotlight. This low-cost index fund lets you own 834 of these stocks in one ETF.
4 Vanguard Funds Worth Buying and Holding for the Next 20 Years Tech and AI have dominated the past several years. The next couple of decades could look a lot different.
Better Cryptocurrency to Buy Now With $1,000: Chainlink vs. XRP One of these coins has a fit with its market, and the other hasn't yet found one.
Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years. Its worst calendar year since 2012 was a loss of around 5.5%. What has that steadiness cost in the good years?
History Says This 1 ETF Could Turn $1,000 Into $38,000 in 20 Years. Here's How. If it grows at the rate it's grown over the past three years, your stake could end up worth over $400,000! (But closer to $38,000 is more likely.)
Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.
Better Biotechnology ETF: First Trust FBT vs. VanEck BBH VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.
Silver ETF Faceoff: Will SLV or SIL Give You Better Exposure to the Shiny Metal? iShares Silver Trust offers lower fees and $30.5B in assets, while Global X Silver Miners ETF delivers dividend income and operational leverage from mining companies.
Better Pharma ETF: iShares IHE vs. State Street XPH IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
Cathie Wood Just Cut Her SpaceX Position. Is It Time to Sell? Cathie Wood loves SpaceX, but her firm sold some of its shares this week.
3 Unique ETFs With Strong Momentum for the End of the Year FTHF, HECO, and GTEK ETFs use niche strategies in emerging markets, hedged crypto, and smaller tech firms, each gaining 40% or more year to date in 2026.
Which Growth-Focused ETF is the Better Fit? Vanguard Morningstar Growth (VUG) or SPDR Small Cap Growth ETF (SLYG)? Vanguard's large-cap fund delivered 47% more wealth over five years, but State Street's small-cap strategy offers lower volatility and higher income.
A Battle of REIT ETFs: Which REIT ETF Offers Better Value for Income-Oriented Investors? State Street's fund charges just 0.08% annually versus iShares' 0.32%, but performance and yield tell a more nuanced story.
Worried About an AI Bubble? You Need To See This 1 Chart Now. History has shown that demand for technology tends to go up and to the right.
